TURALIO (Daiichi Sankyo)
(https://turalio.com) 📸 Data Snapshot: June 20, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
The authority profile is strong, supported by robust Organization schema for Daiichi Sankyo and MedicalWebPage schema targeting an oncologic audience. There are no claims made by unverifiable experts or unnamed sources; the authority is derived directly from the FDA-recognized status of the product. The technical implementation of schema with sameAs links to official social profiles further solidifies the brand’s digital footprint.
The performance claims are limited to regulatory status and disease management data, avoiding the typical breakthrough hyperbole seen in lower-tier biotech sites. The claim that the drug treats adults not likely to improve with surgery is a specific clinical indication rather than a broad marketing promise. The recurrence data provided is grounded in medical classification (diffuse vs. localized) rather than optimistic performance projections.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"audience": "Patient",
"specialty": "Oncologic",
"url": "https://www.turalio.com/en",
"headline": "TURALIO® (pexidartinib), the first FDA-approved, oral treatment for TGCT.",
"description": "TURALIO® (pexidartinib), the first treatment indicated for symptomatic tenosynovial giant cell tumor (TGCT). See full Prescribing Info & Boxed Warning.",
"name": "TURALIO ® (pexidartinib) Patient Homepage",
"about": [
{
"@type": "MedicalCondition",
"name": [
"tenosynovial giant cell tumor",
"giant cell tumor of the tendon sheath",
"pigmented villonodular synovitis",
"TGCT",
"GCT-TS",
"PVNS",
"Symptomatic TGCT"
]
},
{
"@type": "MedicalTherapy",
"name": "TURALIO® (pexidartinib) Capsules",
"guideline": "TURALIO is a prescription medicine used to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS). It is not known if TURALIO is safe and effective in children.",
"adverseOutcome": [
"changes in blood liver tests",
"hair color changes",
"tiredness",
"increased cholesterol level in the blood",
"decreased white blood cells",
"decreased red blood cells",
"swelling in or around your eyes",
"rash",
"itching",
"hives",
"skin redness",
"acne",
"loss of taste or changes in the way things taste",
"decreased phosphate in your blood"
],
"seriousAdverseOutcome": [
"serious liver problems",
"liver failure",
"vanishing bile duct syndrome (VBDS)",
"hepatotoxicity",
"severe liver injury"
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
]
},
{
"@type": "Organization",
"@id": "https://daiichisankyo.us/#organization",
"name": "Daiichi Sankyo",
"alternateName": "DSI",
"url": "https://daiichisankyo.us/",
"sameAs": [
"https://www.linkedin.com/company/daiichi-sankyo/",
"https://x.com/DaiichiSankyoUS",
"https://www.youtube.com/@DaiichiSankyoUS",
"https://www.instagram.com/daiichisankyo_us/"
],
"logo": {
"@type": "ImageObject",
"url": "https://www.turalio.com/-/media/pexi_patient/images/logo/dsi-footer-logo.png",
"caption": "Daiichi Sankyo Logo"
}
}
]
}
/en/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"audience": "Patient",
"specialty": "Oncologic",
"url": "https://www.turalio.com/en",
"headline": "TURALIO® (pexidartinib), the first FDA-approved, oral treatment for TGCT.",
"description": "TURALIO® (pexidartinib), the first treatment indicated for symptomatic tenosynovial giant cell tumor (TGCT). See full Prescribing Info & Boxed Warning.",
"name": "TURALIO ® (pexidartinib) Patient Homepage",
"about": [
{
"@type": "MedicalCondition",
"name": [
"tenosynovial giant cell tumor",
"giant cell tumor of the tendon sheath",
"pigmented villonodular synovitis",
"TGCT",
"GCT-TS",
"PVNS",
"Symptomatic TGCT"
]
},
{
"@type": "MedicalTherapy",
"name": "TURALIO® (pexidartinib) Capsules",
"guideline": "TURALIO is a prescription medicine used to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS). It is not known if TURALIO is safe and effective in children.",
"adverseOutcome": [
"changes in blood liver tests",
"hair color changes",
"tiredness",
"increased cholesterol level in the blood",
"decreased white blood cells",
"decreased red blood cells",
"swelling in or around your eyes",
"rash",
"itching",
"hives",
"skin redness",
"acne",
"loss of taste or changes in the way things taste",
"decreased phosphate in your blood"
],
"seriousAdverseOutcome": [
"serious liver problems",
"liver failure",
"vanishing bile duct syndrome (VBDS)",
"hepatotoxicity",
"severe liver injury"
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
]
},
{
"@type": "Organization",
"@id": "https://daiichisankyo.us/#organization",
"name": "Daiichi Sankyo",
"alternateName": "DSI",
"url": "https://daiichisankyo.us/",
"sameAs": [
"https://www.linkedin.com/company/daiichi-sankyo/",
"https://x.com/DaiichiSankyoUS",
"https://www.youtube.com/@DaiichiSankyoUS",
"https://www.instagram.com/daiichisankyo_us/"
],
"logo": {
"@type": "ImageObject",
"url": "https://www.turalio.com/-/media/pexi_patient/images/logo/dsi-footer-logo.png",
"caption": "Daiichi Sankyo Logo"
}
}
]
}
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /en/ | 0 | 0 |
| /en/what-is-tgct/ | 0 | 0 |
| /en/treating-tgct/ | 0 | 0 |
This page presents a snapshot of public data from TURALIO (Daiichi Sankyo), captured on June 20, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to TURALIO (Daiichi Sankyo): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://turalio.com to view the most current version of its content and see directly what this company is about and what it offers.